StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN – Free Report) in a report released on Friday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Lipocine Price Performance
Shares of LPCN stock opened at $5.07 on Friday. The stock has a market capitalization of $26.97 million, a price-to-earnings ratio of -1.66 and a beta of 1.05. The company’s fifty day simple moving average is $4.53 and its two-hundred day simple moving average is $3.52. Lipocine has a 1 year low of $2.31 and a 1 year high of $7.15.
Lipocine (NASDAQ:LPCN – Get Free Report) last released its quarterly earnings data on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.11. The company had revenue of $0.22 million for the quarter. Equities research analysts anticipate that Lipocine will post -1.49 EPS for the current year.
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Read More
- Five stocks we like better than Lipocine
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Merger or Not, Albertson’s Companies is a Good Buy
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
